The acquisition helped Trividia Health to create new firm Sinocare Meditech.

Freedom Meditech has developed a noninvasive six second eye scan, which secured approval from the US Food and Drug Administration (FDA).

The eye scan uses lens autoflourescence to detect the presence of advanced glycation products or AGEs in the lens of the eye.

Freedom Meditech’s technology holds capacity to be used for screening chronic diseases such as diabetes.

Trividia Health will continue to develop the new technology, in addition to expanding clinical evaluation with an aim to market the next generation device in around 48,000 pharmacies in the US.

As per the American Diabetes Association, around 8.1 million patients in the US remain undiagnosed representing $18bn in future healthcare costs.

Trividia Health president and CEO Scott Verner said: ‘Our retail partners are committed to early intervention and making community pharmacies the focal point for care.

“As the number of in-store clinics continues to grow and the number of screenings continues to expand, this technology will fill the void. We will work with our customers, payors and providers on the best implementation strategy.”

Trividia Health, a wholly-owned subsidiary of Sinocare Group, develops and produces products for diabetes patients.

Under TRUE and store brand labels, the firm supplies blood glucose monitoring and health and wellness solutions to the retail pharmacies, distributors and mail service providers.